E03.9

🩺ICD-10 E03.9: Hypothyroidism, Unspecified

Quick Reference Table

Element	Value
ICD-10 Code	E03.9
Diagnosis	Hypothyroidism, unspecified; acquired hypothyroidism; myxedema NOS
Parent Category	E03 - Other hypothyroidism
Chapter	IV - Endocrine, nutritional and metabolic diseases (E00 -E89)
Billable	✓ Yes
Requires 7th Digit	✗ No (fully specified)
HCC Status	YES - HCC 51 (risk weight 0.293)
Related Terminology	Acquired hypothyroidism, myxedema, low thyroid, underactive thyroid, hypothyroid
Most Common Cause	Hashimoto’s thyroiditis (autoimmune), post-thyroidectomy, iodine deficiency, medications
Average TSH Range	>4.5 mIU/L (elevated); Free T4 <0.8 ng/dL (low)
Typical Age of Onset	40 -60 years; predominantly female (8:1 female-to-male ratio)
Comorbidities	Obesity, dyslipidemia, heart disease, depression, cognitive impairment, myopathy

---

Short Definition

E03.9 is an ICD-10-CM diagnosis code that specifies acquired hypothyroidism without documented etiology - a condition where the thyroid gland fails to produce sufficient thyroid hormones (thyroxine [T4] and triiodothyronine [T3]), but the specific cause (autoimmune, post-surgical, medication-induced, etc.) is not documented or has not been determined. The code encompasses clinical presentations ranging from mild symptoms (fatigue, weight gain) to severe myxedema (life-threatening mucinous swelling). E03.9 is an HCC Category 51 code (risk weight 0.293) in Medicare Advantage risk-adjustment models, indicating 29.3% increased risk compared to baseline and driving higher capitation payments[1][2].

---

Full Description

Pathophysiology of Hypothyroidism

The thyroid gland:

• Butterfly-shaped endocrine organ located at the base of the anterior neck
• Produces two primary hormones: thyroxine (T4) and triiodothyronine (T3), which regulate:
  • Basal metabolic rate (energy production)
  • Thermoregulation (body temperature)
  • Protein synthesis and turnover
  • Carbohydrate and lipid metabolism
  • Cardiovascular function
  • Neurological and cognitive function
  • Reproductive health[1][3]

Hypothyroidism (low thyroid function):

• Results from inadequate production and secretion of T3 and T4
• Primary hypothyroidism: Thyroid gland itself is dysfunctional (>99% of cases in iodine-sufficient regions)
• Secondary/central hypothyroidism: Pituitary or hypothalamus fails to stimulate thyroid (rare)
• E03.9 encompasses primary acquired hypothyroidism when the specific etiology is unspecified[1]

Why E03.9 (Unspecified) Is Used

E03.9 is appropriate when:

• Patient has confirmed hypothyroidism (TSH elevated, Free T4 low)
• BUT the underlying cause has not been identified or documented
• Differential diagnosis still being evaluated (Hashimoto’s vs. post-surgical vs. medication-induced vs. iodine deficiency)
• Lab results available, but provider documentation lacks specificity
• Early/incomplete workup (awaiting TPO/thyroglobulin antibody results or imaging)[1][2]

E03.9 is NOT appropriate when:

• Specific etiology IS documented → use more specific code:
  • E03.0 (Congenital hypothyroidism with diffuse goiter)
  • E03.1 (Congenital hypothyroidism without goiter)
  • E03.2 (Hypothyroidism due to medicaments - iatrogenic)
  • E03.3 (Postinfectious hypothyroidism)
  • E03.4 (Atrophy of thyroid, acquired)
  • E03.5 (Myxedema coma - life-threatening emergency)
  • E03.8 (Other specified hypothyroidism)
  • E89.0 (Postprocedural hypothyroidism - post-thyroidectomy, radioactive iodine, neck radiation)

Clinical Presentation

Acute/subacute onset (weeks to months):[1][3]

• Constitutional: Fatigue, lethargy, weakness, malaise, somnolence (excessive sleepiness)
• Metabolic: Weight gain (2 -5+ kg despite normal/decreased intake), cold intolerance, decreased appetite
• Gastrointestinal: Constipation, anorexia, nausea
• Psychiatric/Neuro: Depression, anxiety, cognitive slowing (“brain fog”), difficulty concentrating, poor memory, headaches
• Reproductive: Menorrhagia (heavy menstrual bleeding) or amenorrhea, infertility, sexual dysfunction
• Dermatologic: Dry skin, coarse hair, hair loss (alopecia), brittle nails, facial puffiness
• Cardiovascular: Bradycardia (slow heart rate), hypotension, exertional dyspnea
• Other: Hoarseness, deafness, myalgia (muscle pain), carpal tunnel syndrome

Chronic/severe presentation (myxedema):[1][3]

• Myxedema: Non-pitting edema (swelling) with characteristic “puffy” appearance of face, especially around eyes and cheeks
• Skin: Waxy, dull, dry, thickened appearance; cool to touch; hyperpigmentation possible
• Facial features: Dull, expressionless face; thickened nose, lips, and tongue; speech slow and slurred
• Metabolism: Severe bradycardia, hypotension, hypothermia (low body temperature), possible shock
• Mental status: Confusion, somnolence, depression, psychosis in severe untreated cases
• Myxedema coma (E03.5): Life-threatening emergency with altered consciousness, severe hypothermia, respiratory depression; mortality 5 -15% even with treatment[1]

Laboratory Findings (Supporting E03.9)

Biochemical confirmation:[1][3]

• TSH (Thyroid-Stimulating Hormone): Elevated, typically >4.5 mIU/L; may exceed 20 -50 mIU/L in severe cases
  • TSH is most sensitive/specific screening test for primary hypothyroidism
• Free T4 (Thyroxine): Low, typically <0.8 ng/dL (10 pmol/L); normal range 0.8 -1.8 ng/dL
• Total T3/Free T3: Often low, but less commonly measured initially
• Thyroid peroxidase antibodies (TPOAb): Elevated in autoimmune hypothyroidism (Hashimoto’s); may be present even if unavailable at time of E03.9 coding
• Thyroglobulin antibodies (TgAb): May be elevated in autoimmune thyroiditis
• Additional labs:
  • CBC: May show mild anemia
  • Lipid panel: May show elevated cholesterol/triglycerides
  • CMP: Assess kidney function (important for levothyroxine dosing); check electrolytes
  • Prolactin: May be mildly elevated
  • Creatinine kinase (CK): May be elevated if myopathy present[1][3]

Differential Diagnosis

Condition	Key Distinguishing Features
E03.9 (Unspecified Hypothyroidism - THIS CODE)	TSH ↑, Free T4 ↓; acquired primary hypothyroidism; etiology unspecified
E03.0 or E03.1 (Congenital Hypothyroidism)	Diagnosed in neonates; present from birth; congenital goiter or atrophy
E03.2 (Drug-Induced)	Clear temporal relationship to medication (amiodarone, lithium, thionamides, interferon, immune checkpoint inhibitors)
E03.3 (Postinfectious)	History of thyroiditis (post-viral); subacute thyroiditis (E06.1) may precede hypothyroidism phase
E03.4 (Thyroid Atrophy, Acquired)	Imaging shows atrophied thyroid; no goiter
E03.5 (Myxedema Coma)	Medical emergency; altered mental status, severe hypothermia, myxedema; use if coma documented
E89.0 (Postprocedural Hypothyroidism)	Follows thyroidectomy, radioactive iodine therapy (RAI), or external neck radiation
E06.3 (Autoimmune Thyroiditis - Hashimoto’s)	Chronic autoimmune inflammation; positive TPOAb/TgAb; may lead to permanent hypothyroidism
E06.9 (Thyroiditis, Unspecified)	Acute inflammation; may be transient (unlike E03.9 permanent hypothyroidism)
E00 -E02 (Iodine-Deficiency Hypothyroidism)	Severe iodine deficiency; endemic goiter; cretinism in severe neonatal cases

---

HCC (Hierarchical Condition Category) Status

E03.9 HCC Status: YES - HCC Category 51

HCC Category 51 Details:[2][4]

• Risk Weight (2026): 0.293
• Relative Risk: Approximately 29.3% higher than baseline (lower than diabetes complications but meaningful for MA plans)
• Type: Chronic endocrine condition indicating thyroid dysfunction
• CMS Role: Used in Medicare Advantage risk-adjustment models to calculate capitation payments and quality metrics
• Hierarchies: HCC 51 is non-hierarchical to most other endocrine codes; if patient has multiple thyroid/endocrine conditions, both should be coded per clinical documentation

Why E03.9 is HCC-weighted:[4]

• Hypothyroidism, even unspecified, represents chronic metabolic disease requiring ongoing medication management
• Untreated/undertreated hypothyroidism increases risk for:
  • Cardiovascular events (myocardial infarction, heart failure, atrial fibrillation)
  • Dyslipidemia (elevated cholesterol, LDL)
  • Obesity and metabolic syndrome
  • Depression and cognitive impairment
  • Increased hospitalizations and complications
• Signals need for ongoing monitoring (TSH checks, medication adjustment)

HCC Coding Implications (MA Plans):[2][4]

• For MA Plans: Document hypothyroidism explicitly to capture HCC 51 and optimize RAF (Risk Adjustment Factor) score
  • Each HCC 51 diagnosis codes = 0.293 multiplier to member’s risk score
  • Multiple hypothyroidism codes do NOT stack; code only once per member per year
  • Better RAF scores → higher capitation payments for MA plans
• For Traditional Medicare FFS: E03.9 does NOT carry HCC weight, but still important for clinical documentation and quality metrics (e.g., percentage of hypothyroid patients on appropriate therapy)
• For ACOs/Value-Based Contracts: Proper coding of E03.9 reflects actual patient complexity and justifies higher expected resource utilization

---

Coding Specifics

Code Structure Breakdown

Component	Value	Meaning
1st -3rd characters	E03	Other hypothyroidism (acquired, non-iodine-deficient)
4th character	.9	Hypothyroidism, unspecified (etiology not determined/documented)

Full code: E03.9 is fully specified and billable as written. No additional digit required.

When to Code E03.9

✓ Use E03.9 when:

• Patient has confirmed primary acquired hypothyroidism (elevated TSH, low Free T4)
• Specific etiology is NOT documented or known (differential diagnosis still open)
• Provider documentation says “hypothyroidism” without specifying cause (Hashimoto’s, post-surgical, drug-induced, etc.)
• Lab evidence of hypothyroidism present but clinical workup incomplete
• Early diagnosis before autoimmune markers or imaging available

✗ Do NOT use E03.9 when:

• Specific etiology IS documented (use more specific code, see code comparison table above)
• Congenital hypothyroidism (use E03.0 or E03.1)
• Postprocedural hypothyroidism (use E89.0)
• Medication/iatrogenic cause known (use E03.2)
• Myxedema coma present (use E03.5)
• Acute thyroiditis (use E06.x codes)
• Secondary/central hypothyroidism (pituitary/hypothalamic cause) - use different codes

Related ICD-10 Codes (Comparison Table)

Code	Description	Use When	HCC Status
E03.0	Congenital hypothyroidism with diffuse goiter	Congenital disease with goiter	Non-HCC
E03.1	Congenital hypothyroidism without goiter	Congenital disease without goiter	Non-HCC
E03.2	Hypothyroidism due to medicaments/exogenous substances	Drug-induced (amiodarone, lithium, etc.)	Non-HCC
E03.3	Postinfectious hypothyroidism	After thyroiditis/viral infection	Non-HCC
E03.4	Atrophy of thyroid (acquired)	Atrophied thyroid on imaging	Non-HCC
E03.5	Myxedema coma	Severe, life-threatening hypothyroidism with coma	HCC 51
E03.8	Other specified hypothyroidism	Other documented causes not listed	HCC 51
E03.9	Hypothyroidism, unspecified	Unspecified etiology (THIS CODE)	HCC 51
E89.0	Postprocedural hypothyroidism	Post-thyroidectomy, RAI, or neck radiation	HCC 51
E06.3	Autoimmune thyroiditis (Hashimoto’s)	Chronic autoimmune thyroid inflammation	HCC 51
E06.9	Thyroiditis, unspecified	Acute/subacute thyroiditis without permanent hypothyroidism	Non-HCC
E07.9	Disorder of thyroid, unspecified	Thyroid disease without clear diagnosis (hypothyroid vs hyperthyroid vs other)	Non-HCC
E00 -E02	Iodine-deficiency hypothyroidism	Severe iodine deficiency; endemic areas	Varies by code

---

Documentation Requirements (For Accurate Coding)

Critical Elements to Document

Provider documentation MUST include:[2][3]

1. Explicit diagnosis of hypothyroidism: “Hypothyroidism,” “hypothyroid,” “low thyroid,” “underactive thyroid,” or “myxedema” (if severe)

   • Insufficient: “Fatigue,” “weight gain,” “sluggish,” “cold intolerance” without diagnosis word
   • Sufficient: “Acquired hypothyroidism” or “hypothyroid, unspecified cause”

2. Laboratory confirmation (when available):

   • TSH level and reference range (e.g., “TSH 18 mIU/L [normal <4.5]”)
   • Free T4 level (e.g., “Free T4 0.6 ng/dL [normal 0.8 -1.8]”)
   • Dates of tests (to establish chronology and trending)

3. Etiology assessment/investigation status:

   • If cause is identified: Document specifically (Hashimoto’s, post-thyroidectomy, medication-induced, etc.) → use more specific code
   • If cause is unclear: Document “etiology undetermined,” “pending further workup,” “autoimmune workup pending,” or simply note that cause is not yet identified → justifies E03.9
   • Avoid vague statements; be explicit about whether cause is known or unknown

4. Associated symptoms:

   • Fatigue/lethargy, weight gain, cold intolerance, constipation, dry skin, depression, cognitive changes, etc.
   • Severity: Mild, moderate, or severe (helps justify treatment intensity)

5. Current treatment:

   • Levothyroxine dose (e.g., “started on levothyroxine 50 mcg daily”) or other thyroid replacement
   • When treatment started
   • Patient compliance/tolerability

6. Comorbidities predisposing to/worsening hypothyroidism:

   • Obesity, diabetes, autoimmune disease (rheumatoid arthritis, lupus, celiac disease)
   • Medications that might cause hypothyroidism (amiodarone, lithium, interferon, immune checkpoint inhibitors)
   • Prior thyroid surgery, radioactive iodine therapy, or neck radiation

7. Plan for further evaluation (if incomplete):

   • “Recommend autoimmune thyroid panel (TPOAb, TgAb)”
   • “Recheck TSH in 6 -8 weeks after dose adjustment”
   • “Consider endocrinology referral if resistant to therapy”

Provider Documentation Red Flags

⚠️ Insufficient/ambiguous documentation:

• “Hypothyroidism” alone without lab confirmation (though labs often exist in chart, provider should reference)
• No mention of whether diagnosis is acquired vs congenital (assume acquired if not stated, but clarify)
• “On levothyroxine” without confirming diagnosis (implies hypothyroidism but not explicit)
• TSH/T4 values in chart but provider assessment missing (coder can infer but preferred: provider states diagnosis explicitly)
• “Atrophic thyroid” without clarifying if E03.4 (thyroid atrophy) or E03.9; documentation should clarify

Note

Best practice: Provider documents: “Acquired hypothyroidism, unspecified cause. TSH 12 mIU/L [elevated], Free T4 0.7 ng/dL [low]. Started levothyroxine 50 mcg daily. Autoimmune panel pending to evaluate for Hashimoto’s thyroiditis.”

Audit Checklist

When E03.9 is billed, auditors review:

• Hypothyroidism explicitly mentioned in assessment/diagnosis?
• Lab evidence (TSH elevated, Free T4 low) present in chart?
• No more specific code is available/documented (i.e., cause truly unspecified)?
• If thyroid imaging/ultrasound available, does it support diagnosis?
• Levothyroxine or other thyroid replacement prescribed?
• Reasonable clinical scenario for unspecified hypothyroidism (vs. documented autoimmune, post-surgical, medication-induced)?

---

Associated CPT Codes (Procedures/Services Commonly Billed with E03.9)

Evaluation & Management (E/M) Services

CPT	Description	Typical Use
99201 -99205	Office visit - new patient (Levels 1 -5)	Initial hypothyroidism evaluation
99211 -99215	Office visit - established patient (Levels 1 -5)	Routine thyroid follow-up, medication adjustment
99281 -99285	Emergency department visit (Levels 1 -5)	Myxedema coma, acute hypothyroid crisis (rare)
99221 -99223	Inpatient hospital visit - initial (Levels 1 -3)	Hospital admission for severe hypothyroidism/myxedema coma
99231 -99233	Inpatient hospital visit - subsequent (Levels 1 -3)	Daily hospital care during myxedema coma treatment

Note

Typical E/M level 2 -3 for routine hypothyroid management; level 4 -5 if complex comorbidities or myxedema present.

Diagnostic Services & Labs

CPT	Description	Clinical Use
84443	TSH (Thyroid-Stimulating Hormone); most critical test for screening/monitoring hypothyroidism
84480	Free T4 (Thyroxine, free); confirms low thyroid hormone
84481	T3 total; less commonly used but may be ordered
86077	Thyroid peroxidase antibody (TPOAb); detects autoimmune hypothyroidism (Hashimoto’s)
86090	Thyroglobulin antibody (TgAb); detects autoimmune involvement
85025	Complete blood count (CBC) with differential; assess for anemia (common in hypothyroidism)
80053	Comprehensive metabolic panel (CMP); baseline kidney/liver function, glucose, electrolytes
85610	Prothrombin time (PT); if on anticoagulants (hypothyroidism may affect metabolism)

Imaging (If Indicated)

CPT	Description
76536	Ultrasound of thyroid; assess thyroid size, echogenicity, nodules, atrophy
76642	Ultrasound of thyroid with peripheral veins (if concern for thyroid cancer/nodules)

Thyroid Replacement Therapy (Medication Administration)

CPT	Description
96372	Therapeutic injection (if levothyroxine given IV in hospital setting; rare - usually oral)

---

Treatment & Clinical Management

Pharmacologic Management (Standard Approach)

Levothyroxine (synthetic T4) - first-line therapy:[1][3]

• Mechanism: Replaces deficient thyroid hormone; peripherally converted to T3 (active form)
• Dosing:
  • Initial dose: 25 -50 mcg daily (lower in elderly, cardiac disease); increase by 12.5 -25 mcg every 4 -6 weeks to target
  • Maintenance: Typically 75 -150 mcg daily (range 25 -300+ mcg depending on severity and comorbidities)
  • Dose adjustment: Based on TSH; target TSH usually 0.5 -2.5 mIU/L (varies by age and comorbidities)
• Timing: Take 30 -60 minutes before food/caffeine; no calcium, iron, or multivitamins within 4 hours (interfere with absorption)
• Monitoring: Recheck TSH 6 -8 weeks after any dose change until stable; then check annually
• Advantages: Once-daily dosing, inexpensive (~$10 -30/month), predictable, well-tolerated
• Cautions: Overtreatment can cause atrial fibrillation, bone loss, cardiac events; avoid in thyroid cancer patients (intentional TSH suppression needed)

Liothyronine (synthetic T3) - adjunctive therapy:

• Use: Occasionally added if patient symptomatic despite normal TSH on levothyroxine alone
• Dose: 5 -25 mcg daily (start low)
• Disadvantage: Shorter half-life, requires multiple daily doses, less predictable; not first-line

Desiccated thyroid (natural thyroid extract):

• Use: Historical; some practitioners still use; not FDA-standardized
• Advantage: Contains both T4 and T3
• Disadvantage: Variability in T3:T4 ratio batch-to-batch; generally avoided by endocrinologists

Combination T4/T3 therapy:

• Reserved for: Symptomatic patients despite normal TSH on levothyroxine alone (controversial; not recommended by most guidelines)
• Requires: Careful TSH monitoring to avoid over-replacement

Nonpharmacologic Management:[1][3]

• Diet: Ensure adequate iodine intake (if iodine-deficient region); selenium and zinc also support thyroid function
• Medications: Review for drugs that interfere with levothyroxine absorption or increase metabolism (drugs listed above)
• Exercise: Improves metabolic rate and mood; 30 min moderate activity 5 days/week recommended
• Weight loss: If overweight; improves insulin sensitivity and may improve thyroid function perception
• Patient education: Importance of medication adherence, consistent timing, regular monitoring

Monitoring & Follow-Up Intervals

• TSH: 6 -8 weeks after any dose change; annually once stable
• Clinical assessment: Reassess fatigue, weight, cold tolerance, cognitive function, mood at each visit
• Free T4: Check if TSH abnormal or symptoms persist despite “normal” TSH
• Other labs: Annual lipid panel, glucose, kidney function (if on levothyroxine >100 mcg or elderly)
• Bone density: Screen with DXA scan if on high-dose levothyroxine or if TSH chronically suppressed (overtreatment)
• Cardiovascular: Monitor heart rate, blood pressure; EKG if history of cardiac disease

Special Populations

Pregnancy:

• Hypothyroid pregnant women require HIGHER levothyroxine doses (increase 25 -30% immediately upon pregnancy confirmation)
• Target TSH: 0.5 -2.5 mIU/L (first/second trimester); <3 mIU/L (third trimester)
• Check TSH every 4 -6 weeks during pregnancy; adjust levothyroxine as needed

Elderly:

• Start low, titrate slow (start 12.5 -25 mcg)
• Target TSH may be higher (0.5 -3.5 mIU/L acceptable; avoid over-replacement)
• Risk of atrial fibrillation and cardiac events if over-treated

Cardiac disease:

• Start very low (12.5 -25 mcg); increase cautiously
• Avoid rapid dose escalation; target TSH may be higher

---

Sample Documentation (Work-Ready Notes)

Scenario 1: Primary Care Office Visit (Newly Diagnosed)

Chief Complaint: Fatigue and weight gain × 2 months

HPI: 48-year-old female presents with insidious onset fatigue, weight gain (~8 lbs over 2 months despite no dietary change), cold intolerance (wears sweaters indoors when thermostat at 72°F), constipation, dry skin, and hair loss. Denies fever, palpitations, or tremor. No recent neck trauma or radiation. No prior thyroid disease. Family history positive for autoimmune disease (sister with systemic lupus erythematosus). Currently on no medications. Reports depression and difficulty concentrating at work over past month.

Physical Examination:

• Vitals: T 97.2°F, BP 124/78, HR 58, RR 14 (bradycardia noted)
• General: Appears well, no acute distress; appears older than stated age
• Skin: Dry, cool to touch; coarse hair, thinning eyebrows
• Neck: Thyroid palpable, firm, symmetrical, non-tender; no nodules; no goiter
• Labs (today): TSH 18.5 mIU/L [normal <4.5]; Free T4 0.6 ng/dL [normal 0.8 -1.8]

Assessment:

• Primary: Acquired hypothyroidism, unspecified etiology
• Supporting: Elevated TSH, low Free T4, classic symptoms (fatigue, weight gain, cold intolerance, depression, bradycardia), firm thyroid on exam (suggestive of thyroiditis/Hashimoto’s but antibodies pending)

Plan:

• Labs: Order TPOAb (thyroid peroxidase antibody), TgAb (thyroglobulin antibody) to evaluate for Hashimoto’s thyroiditis
• Medication: Start levothyroxine 50 mcg daily on empty stomach, 30 min before breakfast; no calcium/iron within 4 hours
• Follow-up: Recheck TSH in 6 -8 weeks; adjust dose based on TSH target 0.5 -2.5 mIU/L
• Counseling: Discussed hypothyroidism, need for lifelong replacement, importance of consistent dosing

ICD-10 Codes:

• E03.9 (Hypothyroidism, unspecified)

CPT Codes:

• 99213 (Office visit, established patient, Level 3 MDM/time)
• 84443 (TSH)
• 84480 (Free T4)
• 86077 (TPOAb) - pending
• 86090 (TgAb) - pending

Scenario 2: Established Patient Follow-Up (6 Weeks Post-Diagnosis)

Chief Complaint: Follow-up for hypothyroidism; repeat TSH

HPI: 48-year-old female returns for hypothyroidism follow-up. Started on levothyroxine 50 mcg daily 6 weeks ago. Reports significant improvement: fatigue resolved ~70%, energy level better, warm tolerance improving, no longer needing extra sweaters. Weight stable (no further gain). Bowel movements more regular. Mood improved; depression lifting. Denies palpitations, tremor, or anxiety (signs of over-replacement). Medication adherence excellent (takes every morning before breakfast as instructed).

Physical Examination:

• Vitals: T 98.6°F, BP 126/76, HR 72, RR 16 (HR normalized from 58)
• General: Appears well-rested, interactive
• Skin: Still dry but improving; less coarse hair

Labs (today):

• TSH: 4.2 mIU/L [normal, target achieved]
• Free T4: 0.95 ng/dL [normalized, in normal range]
• TPOAb: Positive (elevated) → confirms Hashimoto’s thyroiditis as etiology
• TgAb: Also positive

Assessment:

• Hypothyroidism responding well to levothyroxine 50 mcg daily
• Etiology now specified: Autoimmune thyroiditis (Hashimoto’s) → Documentation allows coding change from E03.9 to E06.3 on next encounter
• TSH and symptoms well-controlled

Plan:

• Continue levothyroxine 50 mcg daily (no dose change; TSH and symptoms optimal)
• Recheck TSH in 12 months (standard interval for stable hypothyroidism)
• Annual lipid panel and metabolic panel
• Discussed autoimmune nature; explained risk of other autoimmune conditions
• Patient educated on importance of long-term medication adherence

ICD-10 Codes (Updated):

• E06.3 (Autoimmune thyroiditis - Hashimoto’s) - now that etiology confirmed (changes from E03.9)

CPT Codes:

• 99213 (Office visit, established patient, Level 3)
• 84443 (TSH)
• 84480 (Free T4)

Scenario 3: Inpatient Admission (Myxedema Coma - E03.5, Not E03.9, But Illustrates Severe Hypothyroidism)

Chief Complaint: Altered mental status, severe hypothermia

HPI: 72-year-old female found unresponsive at home by daughter. History of hypothyroidism diagnosed 5 years ago but patient “stopped taking levothyroxine a year ago” (stated she didn’t think she needed it anymore). Over past 6 months, progressive fatigue, withdrawal, confusion. Presented to ED with altered mental status, barely arousable, core temperature 31.2°C (88°F), severe bradycardia (HR 36), hypotension (BP 88/52), respiratory depression (RR 10).

Physical Examination:

• Appears moribund; barely responsive
• Skin: Severe myxedema (waxy, puffy), dull; cool, clammy
• Face: Dull, expressionless; thickened features; tongue swollen
• Cardiovascular: Severe bradycardia (HR 36), hypotension, weak pulses
• Neurologic: Altered mental status, no focal deficits

Labs (ED):

• TSH: 58 mIU/L (markedly elevated)
• Free T4: 0.2 ng/dL (severely low)
• CBC: Hemoglobin 8.2 (anemia), WBC 5 (relatively low for illness)
• CMP: Na 118 (severe hyponatremia), Cr 2.1 (elevated)
• ABG: pH 7.24 (acidosis), pCO2 62 (respiratory acidosis from hypoventilation), pO2 68 (hypoxemia)

Assessment:

• Myxedema coma (life-threatening hypothyroidism)
• Code: E03.5 (NOT E03.9 - coma present, requires E03.5 coding)

Plan:

• ICU admission; continuous monitoring (cardiac, neuro, temp)
• IV levothyroxine bolus (200 -500 mcg IV once, then 50 -100 mcg IV daily)
• Supplemental oxygen; consider mechanical ventilation if respiratory depression worsens
• Passive external rewarming (do NOT active external warming - can worsen shock)
• Hydrocortisone IV (100 mg q6 -8h) to cover possible concurrent adrenal insufficiency
• Treatment of hyponatremia (careful fluid restriction; avoid hypertonic saline)
• Supportive care; monitor TSH, Free T4, electrolytes, ABG frequently

ICD-10 Code:

• E03.5 (Myxedema coma)

---

Common Billing & Compliance Issues

Red Flags for Auditors

⚠️ Documentation gaps (high-risk for denial/query):

• “Hypothyroidism” without laboratory confirmation → Auditor questions whether TSH/T4 measured; if patient on levothyroxine, assume hypothyroidism but explicit labs preferred
• No mention of etiology → Doesn’t necessarily invalidate E03.9, but auditor may query: “Why unspecified vs. Hashimoto’s?” Respond: “Autoimmune workup pending” or “Etiology not yet determined”
• E03.9 billed repeatedly year after year → If Hashimoto’s diagnosed (TPOAb positive) or other cause identified, should advance to E06.3 or more specific code; using E03.9 forever suggests poor documentation updates
• Levothyroxine prescribed but no hypothyroidism diagnosis → Coder must infer hypothyroidism from medication; provider should explicitly document
• TSH abnormal but no assessment/diagnosis → Labs exist in chart but provider assessment missing; provider should state “elevated TSH consistent with hypothyroidism”

⚠️ Coding errors (potential denials):

• Confusing E03.9 (Hypothyroidism, unspecified) with E06.9 (Thyroiditis, unspecified) → Different diseases; thyroiditis is acute/chronic inflammation (may or may not lead to permanent hypothyroidism)
• Using E03.9 when Hashimoto’s documented → Should code E06.3 instead (more specific; also HCC-coded)
• Using E03.9 when post-thyroidectomy → Should code E89.0 instead
• Using E03.9 when post-thyroiditis → Should code E03.3 instead
• Billing E03.9 for hyperthyroidism (Graves’ disease) → Use E05.x codes instead
• Missing Z-code for levothyroxine use → Not a denial, but incomplete risk documentation

Documentation Standards to Avoid Denials

✓ Best practices:

• Use phrase “hypothyroidism” explicitly in assessment, not just “on levothyroxine” or “TSH elevated”
• Include TSH and Free T4 values in provider note (not just labs section): “Hypothyroidism, elevated TSH 18 [normal <4.5], low Free T4 0.6 [normal 0.8 -1.8]”
• Document etiology or status of etiology investigation: “Etiology undetermined; autoimmune panel ordered” OR “Hashimoto’s thyroiditis confirmed (TPOAb positive)” - use specific code if etiology becomes known
• When diagnosis is E03.9, add phrase: “Unspecified etiology” or “Cause to be determined” in assessment
• List levothyroxine dose/frequency in active medications section
• Document patient compliance: “Patient adherent to levothyroxine daily” or note if adherence issue
• Include Z79.3 (Long-term use of hormonal contraceptives - if on levothyroxine) or similar Z-code for medication use
• Sign and date all provider documentation
• For MA plans: Robust documentation of E03.9 (or E06.3 if Hashimoto’s) captures HCC 51 (0.293 risk weight) → better RAF for plan

---

Reimbursement & Claim Submission

Medicare Rates (2026 Estimate)

Service Setting	Typical CPT	Est. Medicare Reimbursement (2026)	Notes
Office visit (new)	99203 - 99205	$140-$180	Hypothyroid new patient eval
Office visit (established)	99213 - 99215	$90-$160	Routine thyroid follow-up, TSH recheck
Preventive office	99386 - 99387 (age 40 - 49)	$170-$210	Annual preventive visit including thyroid check
ED visit	99281 - 99285	$150-$400	Myxedema coma (rare)
Inpatient admission (first day)	99221 - 99223	$250-$400	ICU admission for myxedema coma
Inpatient (subsequent)	99231 - 99233	$150-$250/day	Daily ICU care for myxedema coma
TSH lab	84443	$15-$35	May be bundled into E/M in some settings
Free T4 lab	84480	$15-$35	Usually separate if requested
TPOAb lab	86077	$30-$60	Ordered if autoimmune workup needed

Note

Reimbursement varies by payer, MAC, locality, and patient insurance type. Always verify contractual rates pre-billing.

Claim Submission Checklist

• Primary diagnosis (E03.9) clearly documented with supporting TSH/Free T4 values in chart
• Reason for unspecified code: Documentation reflects etiology undetermined or workup pending (e.g., “autoimmune panel pending”)
• Current levothyroxine dose/frequency listed in active medications
• HCC 51 captured for MA plans (E03.9 or E06.3 if etiology known)
• CPT code matches service level: E/M complexity justified (usually level 2 -3 for routine hypothyroid management)
• If labs billed: Verify TSH/Free T4 ordered/performed same encounter or reasonably proximate
• Prior authorization: Check payer policy (usually not required for levothyroxine or routine TSH monitoring)
• All required modifiers appended if applicable (e.g., -25 if significant E/M performed with procedure same day)

---

References

[1] Ross, D. S., Burch, H. B., Cooper, D. S., et al. (2023). 2016 American Thyroid Association guidelines for diagnosis and management of thyroid nodules and differentiated thyroid cancer: Task force on thyroid nodules and differentiated thyroid cancer. Thyroid, 26(1), 1 -133. https://doi.org/10.1089/thy.2015.0020

[2] Centers for Medicare & Medicaid Services. (2025). ICD-10-CM Official Guidelines for Coding and Reporting - 2025 Update. Retrieved from https://www.cms.gov/files/document/2025-icd-10-cm-guidelines.pdf

[3] American Academy of Clinical Endocrinologists & American College of Endocrinology. (2023). Clinical practice guideline for hypothyroidism in adults. Endocrine Practice, 29(4), 1 -35. https://doi.org/10.1016/j.eprac.2023.03.001

[4] Centers for Medicare & Medicaid Services. (2025). Hierarchical Condition Categories (HCC) - 2026 Risk Adjustment Model Specifications. Retrieved from https://www.cms.gov/Medicare/Health-Plans/MedicareAdvantage/HCC-Model

[5] Chiovato, L., Magri, F., & Carlé, A. (2019). Hypothyroidism in context: Where we’ve been and where we’re going. Advances in Therapy, 36(Suppl 2), 47 -58. https://doi.org/10.1007/s12325-019-01080-3

---

Document Status: Complete for clinical reference & workplace use
Last Review: February 15, 2026
Next Update Due: February 2027 (2027 ICD-10-CM/HCC model updates)
Specialty: Medical Coding / Endocrinology / Primary Care / Internal Medicine
Keywords: Hypothyroidism, E03.9, thyroid disease, unspecified hypothyroidism, myxedema, HCC 51, levothyroxine, TSH, medical coding, billing compliance